Tel Aviv, Israel — BAIBYS™ Fertility, a pioneering force in reproductive technology, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application titled “Automated Spermatozoa Candidate Identification.” This milestone represents a significant advancement in the company’s intellectual property portfolio and strengthens its position in the global fertility technology market.

The allowed patent covers BAIBYS™ Fertility’s proprietary artificial intelligence technology that revolutionizes the sperm analysis process, offering unprecedented accuracy and efficiency in identifying viable sperm candidates for assisted reproductive procedures. This technological breakthrough has the potential to significantly improve success rates in fertility treatments while reducing costs and time-to-pregnancy for patients worldwide.

The global fertility market is projected to reach $110 billion by 2028, with technological innovation driving significant growth. BAIBYS™ Fertility’s patent-protected technology addresses a critical need in this expanding market, offering fertility clinics and healthcare providers a more reliable and efficient solution for sperm analysis and selection.

Key Features of the Patented Technology:

• Advanced AI algorithms for precise sperm morphology analysis
• Real-time identification of optimal sperm candidates
• Improved accuracy in sperm selection for IVF
• Automatic robotic pickup and isolation of selected cells for injection
• Streamlined workflow integration for fertility clinics

The company is currently in discussions with leading fertility clinics and healthcare providers globally for potential partnerships and implementation of its technology. This patent allowance is expected to accelerate commercialization efforts and attract strategic partnerships worldwide.